Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
|
(d) Exhibits Exhibit Number Description |
|
99.1 Press Release of Nuo Therapeutics, Inc., dated March |
About Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ)
Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc. Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Recent Trading Information
Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) closed its last trading session at 0.0120 with 51,009 shares trading hands.
